Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy Regimens for Newly Diagnosed Lymphoblastic Lymphoma
NCT00004228Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Jun 2000
- Primary completion
- Aug 2008
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Replacement Enzymes
- Countries
- 5
01
Overview
A Phase 3 trial of asparaginase escherichia coli, cyclophosphamide, cytarabine, daunorubicin, dexamethasone in lymphoblastic lymphoma (LL), sponsored by Children's Oncology Group. Started Jun 2000; status: completed.
02
Drugs
asparaginase escherichia colicyclophosphamidecytarabinedaunorubicindexamethasone
03
Conditions
lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT00004228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004228.